NY-KYNDRYL
20.9.2022 06:02:37 CEST | Business Wire | Press release
Kyndryl (NYSE: KD), the world's largest IT infrastructure services provider, today announced a new open integration platform giving business leaders real-time insights into their complex IT estates, and unprecedented control over customizing their mission-critical operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005855/en/
Kyndryl Introduces New Platform, Kyndryl Bridge, to Orchestrate IT Estates and Drive Business Growth (Graphic: Business Wire)
Kyndryl Bridge leverages Kyndryl’s core technology strengths. It marshals decades of expertise, operational data patterns and IP to generate actionable insights that redefine how enterprises improve and accelerate their AI-powered analytics and business objectives. In doing so, it creates an uninterrupted path between digital business and the tech that drives it. Kyndryl Bridge is designed to meet customers where they are today, enabling interoperability that maximizes the value of tools they already know and trust.
“Dealing with complexity is what Kyndryl does best, and what customers need most. Kyndryl Bridge will be a way for our customers, and Kyndryl, to run their mission-critical infrastructure and digital transformation journeys better,” said Martin Schroeter, Kyndryl’s Chairman and Chief Executive Officer. “Kyndryl is committed to transforming how IT services are delivered, and Kyndryl Bridge is core to our long-term strategic mission to grow our ecosystem of alliance partners, use tools and IP to create a robust advanced delivery system, and ultimately dedicate more expertise and focus to best serve customers at scale.”
Across the global economy, digital modernization efforts sit at the top of today’s business agendas, with 60 percent of CIOs citing it as their most critical growth driver in 2022. However, business and technology complexity — along with a shortage of critical IT skills — has slowed progress for most enterprises. Kyndryl is accelerating its customers’ digital business journeys by innovating to deliver solutions through platform-enabled services.
“Enterprise IT leaders today are responsible for the management of increasingly-complex IT estates that demand greater oversight, interoperability, and AI-powered analytics to avert challenges and downtime,” says David Tapper, program VP, Outsourcing and Managed Cloud Service at IDC. “The ability of Kyndryl Bridge to connect the many tools, workflows, and processes in which enterprises have spent years investing, while delivering real-time, actionable insights and recommendations, is a powerful proposition for enterprises throughout the global economy.”
Kyndryl Bridge integrates and connects the complex management and process tools that enterprises throughout the global economy rely upon. Its capabilities have, on average, reduced the number of incidents per server per month for enterprises by 74 percent.
“By enabling leaders to focus less on managing IT systems, they can build and support their digital business strategies while freeing up IT resources for higher-value work,” said Antoine Shagoury, Kyndryl’s Chief Technology Officer. “It provides greater access and control over critical tools, and Kyndryl experts in cloud, data and AI, security and resiliency, mainframe modernization, and other important aspects of the IT estate.”
Designed with configurability in mind, Kyndryl Bridge is evolving to deploy ready-made, industrial scale solutions from Kyndryl and its broad and growing partner ecosystem. Its intelligent management tools, powered by automation and AI, will provide technology leaders with real-time insights to prevent downtime and better forecast future needs and costs.
“As customers accelerate their digital transformation, Kyndryl’s new digital integration platform can help provide rich data insights, solutions automation, and services delivery expertise,” said Nick Holden, Vice President, Cisco Global Strategic Partners and Co-sell. “Kyndryl Bridge is a big step forward to enable Kyndryl and Cisco to deliver business outcomes that our joint customers are demanding.”
For customers, the platform maximizes the benefits of native multi-cloud capabilities and delivers an ‘as-a-service’ (aaS) operating environment. It is designed to be a strategic digital hub, that will continue to expand and grow over time, connecting Kyndryl’s advanced technology and tooling with a deep bench of industry expertise and forward-thinking innovators across virtually every sector of the global economy.
About Kyndryl
Kyndryl (NYSE: KD) is the world’s largest IT infrastructure services provider serving thousands of enterprise customers in more than 60 countries. The Company designs, builds, manages, and modernizes the complex, mission-critical information systems that the world depends on every day. For more information, visit www.kyndryl.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom